Johnson & Johnson reported strong Q2 sales of $584 million for Spravato, a nasal spray for treatment-resistant depression, signaling robust market potential for psychedelic drugs. Jefferies highlights this growth supports the commercial viability of psychedelics in mental health, with J&J aiming for $3-3.5 billion annual sales by 2027-2028 and peak sales up to $5 billion. The report also notes upcoming milestones for other psychedelic developers like Compass Pathways and AtaiBeckley, suggesting growing investor interest and regulatory support in the sector.
Jim Cramer and financial analysts recommend investors diversify portfolios with stable, dividend-paying stocks like consumer staples, pharmaceuticals, and waste management to protect against tech sector downturns. These 'quiet winners' continue to de...
Johnson & Johnson's recent quarterly report showed its MedTech segment sales fell short of Wall Street expectations, primarily due to pricing pressures in China and budget cuts in Europe. This shortfall caused the company's shares to decline, impacti...
Johnson & Johnson reported strong Q3 earnings with a 6% sales increase and raised its full-year guidance, yet its stock dropped nearly 6% after a weak MedTech segment performance and costs from recent acquisitions. Despite the selloff, key drug sales...
Johnson & Johnson reported resilient sales growth and exceeded earnings expectations, driven by promising results in its Innovative Medicine segment and potential growth from its MedTech OTTAVA system. However, softness in profitability and ongoing r...
Johnson & Johnson reported a 6% revenue increase to $25.4 billion in Q3 2026, but earnings per share (EPS) declined 7.5% year-on-year, causing the stock to fall 5%. The company set aside $5.5 billion to resolve talc litigation, aiming for 95% plainti...
